p63、P-gp、GST-π及Topo-Ⅱ在食管鳞癌组织中的表达

Expression of p63,P-gp,GST-π and Topo-Ⅱ in esophageal squamous cell carcinoma

目的:观察比较p63、P-糖蛋白(P-gp)、谷甘胱肽-S-转移酶π(GST-π)、DNA拓扑异构酶(Topo-Ⅱ)在食管癌中的表达情况,并探讨其关系和临床意义。方法:采用免疫组化方法对168例食管鳞癌组织中p63、P-gp、GST-π、Topo-Ⅱ蛋白进行检测,分析其与病理特征的关系及协同表达的意义。结果:p63、P-gp、GST-π、Topo-Ⅱ蛋白在食管鳞癌中的阳性表达率分别为81.0%、57.1%、71.4%、78.6%。p63的表达与肿瘤的临床分期、浸润深度、淋巴结转移相关(P<0.05),P-gp和TopoⅡ的表达与淋巴转移有关(P<0.05),GST-π的表达与肿瘤分化程度、淋巴结转移有关(P<0.05)。p63的阳性表达与P-gp、GST-π呈正相关(r=0.193、0.197,P<0.05),P-gp与GST-π表达呈正相关(r=0.224,P<0.05),P-gp与TopoⅡ表达呈负相关(r=-0.218,P<0.05)。结论:p63、P-gp、GST-π及Topo-Ⅱ均与食管癌发生发展有关,对肿瘤化疗方案的选择和预后判断有重要的临床意义。

Objective： To observe and compare the expression of p63,P-glycoprotein（ P-gp）,glutathione Stransferase π（ GST-π） and DNA topoisomerase Ⅱ（ Topo-Ⅱ） in esophageal squamous cell carcinoma and discuss the relationships and clincal significance. Methods： The expression of p63,P-gp,GST-π and Topo-Ⅱ in 168 patients with esophageal squamous cell carcinoma were detected by immunohistochemistry, analyzing the relationship of clinicpathological characteristics and the meaning of co-expression. Results： The positive rate of p63,P-gp,GST-π and Topo-Ⅱ in esophageal squamous cell carcinoma was 81. 0%,57. 1%,71. 4% and78. 6%. p63 positive expression was significantly related to the patients’ esophageal clinical stage,invasion degreeand lymph node metastasis（ P 〈 0. 05）. The expression of P-gp and Topo-Ⅱ were related to the lymph node metastasis（ P 〈 0. 05）. GST-π was related to the differentiation degree of esophageal cancer tissue and the lymph node metastasis（ P 〈 0. 05）. P-gp and GST-π separately had obviously positive correlation with p63（ P 〈 0. 05）.Positive correlation between the expreesion of P-gp and GST-π was observed（ P 〈 0. 05）,but there was a negative correlation between the expreesion of P-gp and Topo-Ⅱ（ P 〈 0. 05）. Conclusion： p63,P-gp,GST-πand Topo-Ⅱmay probably involve in the tumorigenesis and progress in esophageal squamous cell carcinoma,also might be used in the selection of chemotherapy regimens and in the prognosis of esophageal cancer.